
Novartis in US$465m deal with 3B Pharmaceuticals GmbH
Under the agreement, which foresees US$425m in milestones plus royalities on future sales for 3B Pharmaceuticals GmbH (3BP), Basel-based pharma...

Neurodegenerative disorders are being fought with €28m
The Danish biotech Teitur Trophics ApS, aiming to treat chronic neurological disorders, has completed a €28m Series A funding. With the money, Teitur...

Tay Therapeutics in licensing deal with VYNE Therapeutics
Tay Therapeutics Ltd’s exclusive license deal with VYNE Therapeutics Inc. on the oral BET inhibitor, TAY-B2 (now known as VYN201) forsees an upfront...

German-Chinese ADC collaboration
Under the terms of the agreement, DualityBio (Shanghai) cashes in $170m upfront plus potential milestones of about $1.5bn. Additionally, DualityBio...

Upscaling AAV gene therapy
Mid-March marks the start of the collaboration of Remedium Bio Inc. and Biovial Oy on an AAV gene therapy for osteoarthritis. Rheumatology and...

DiogenX SA raises €27.5M in Series A financing
The Marseille-based specialist for beta cell regeneration announced it want to use the proceeds to advance its first-in-class regenerative treatment...

Phialogics AG bags pre-seed financing
Basel-based Phialogics AG, which was spun-off from Fraunhofer Institute for Immune Pathology and Immune Tolerance in 2021, has cashed in a pre-seed...